Lactobacillus vaccine - AmVac

Drug Profile

Lactobacillus vaccine - AmVac

Alternative Names: AMV 100; FemiVac; GyneVac; Lactobacillus acidophilus product (Gynevac) - AmVac; Preservative-free variant of FemiVac - AmVac; Vaginal infections immunotherapeutic - AmVac

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator Vakcina Kft
  • Developer AmVac; Medinserv; Vakcina Kft
  • Class Bacterial vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Bacterial vaginosis; Trichomoniasis

Most Recent Events

  • 12 Apr 2016 No recent reports on development identified - Registered for Bacterial vaginosis in Georgia (IM)
  • 10 Jun 2014 AmVac initiates the phase III LATVAC trial for Bacterial vaginosis in Hungary (EudraCT2013-002918-12)
  • 27 Jan 2014 Registered for Bacterial vaginosis in Georgia (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top